Bioventus has completed the acquisition of Misonix—a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicines that are designed to enhance clinical outcomes— for cash and common stock.
According to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus. Together the company will have a significant sales force focused across surgical applications in spinal fusion, neurosurgery of the cranium and wound treatments including diabetic foot ulcers, say the company.
Ken Reali, CEO of Bioventus, added: “The commercial reach of the new Bioventus is significantly broader, deeper and even more global. The acquisition has significant revenue growth opportunities via sales call point synergies that we share with Misonix including spinal and lower extremity surgeons.
“We expect it will accelerate the adoption of the recently launched neXus platform used to facilitate ultrasonic procedures across spinal decompressions using the BoneScalpel, SonaStar for tumour ablation in the cranium and SonicOne for tissue debridement in chronic wounds.”
Stavros Vizirgianakis and Patrick Beyer, each of whom were members of Misonix’s board of directors, have now joined the Bioventus board of directors.
